Form 4: MiNK Therapeutics Director Barbara Ryan Acquires Shares Through Restricted Stock Units

Director Barbara Ryan of MiNK Therapeutics acquired 24,229 shares of common stock through restricted stock units (RSUs) in lieu of cash retainers.

Summary

• Barbara Ryan, a director at MiNK Therapeutics, acquired 24,229 shares of common stock on December 1, 2024.
• The shares were obtained through restricted stock units (RSUs) granted in lieu of cash retainers for board and committee compensation.
• The RSUs will vest one month from the grant date.
• The price per share was $0.73.
• Following the transaction, Ms. Ryan directly owns 150,336 shares of common stock.

Sentiment

Score: 7

Explanation: The transaction is a routine part of director compensation and indicates confidence in the company, but it is not a major event.

Positives

• The acquisition of shares by a director demonstrates confidence in the company.
• The use of RSUs in lieu of cash retainers can be seen as a positive for the company's cash flow.

Industry Context

This is a standard transaction for directors of publicly traded companies, often used as part of their compensation package.

Comparison to Industry Standards

• The use of RSUs for director compensation is a common practice among publicly traded companies.
• The vesting period of one month is relatively short, which may indicate a desire to quickly align director interests with shareholder value.

Stakeholder Impact

• The transaction increases the director's stake in the company, aligning her interests with shareholders.

Key Dates

Keywords

MiNK Therapeutics, Director, Barbara Ryan, Restricted Stock Units, RSUs, Share Acquisition, Beneficial Ownership, Form 4